FibroBiologics, Inc.
FBLG- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001958777
No open-market purchases or sales by FibroBiologics, Inc. insiders were filed in the last 90 days; 17 institutions reported holding it in 13F filings for Q2 2026, worth $269.7K in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 8, 2026, 3:06 PM ET
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | – | – | – |
| Operating expenses | $16.6M | $13.7M | $8.89M |
| Research and development | $7.41M | $4.50M | $2.37M |
| Selling, general and administrative | $9.24M | $9.23M | $6.52M |
| Operating income | -$16.6M | -$13.7M | -$8.89M |
| Interest expense | $204.0K | $20.0K | $147.0K |
| Income tax | $0 | $0 | $0 |
| Net income | -$18.6M | -$11.2M | -$16.5M |
| EPS, basic | $-0.42 | $-0.34 | $-0.68 |
| EPS, diluted | $-0.42 | $-0.34 | $-0.68 |
| Weighted shares, basic | 44.7M | 32.9M | 28.2M |
| Weighted shares, diluted | 44.7M | 32.9M | 28.2M |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | – | – | – |
| Cash and equivalents | $4.89M | $14.0M | $9.16M |
| Total current assets | $6.35M | $14.2M | $9.21M |
| Property, plant and equipment | $842.0K | $824.0K | $797.0K |
| Total assets | $9.62M | $16.4M | $11.8M |
| Total current liabilities | $1.76M | $12.7M | $9.18M |
| Total liabilities | $3.46M | $13.7M | $10.6M |
| Shareholders' equity | $6.16M | $2.73M | $1.25M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 |
| Filing | 10-K | 10-K | 10-K |
| Reported | – | – | – |
| Operating cash flow | -$16.4M | -$11.9M | -$6.40M |
| Capital expenditures | $262.0K | $184.0K | $495.0K |
| Free cash flow | -$16.7M | -$12.1M | -$6.90M |
| Stock-based compensation | $2.69M | $2.22M | $1.76M |
| Investing cash flow | -$262.0K | -$184.0K | -$495.0K |
| Financing cash flow | $7.57M | $16.9M | $13.8M |
| Net change in cash | -$9.09M | $4.82M | $6.90M |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Jul 31, 2026 | 6.66M | −84.1% | SEC |
| May 1, 2026 | 5.21M | −86.4% | SEC |
| Feb 24, 2026 | 67.6M | +79.1% | SEC |
| Oct 31, 2025 | 51.5M | +48.5% | SEC |
| Jul 30, 2025 | 41.9M | +19.1% | SEC |
| May 13, 2025 | 38.3M | +16.9% | SEC |
| Mar 28, 2025 | 37.7M | +15.6% | SEC |
| Nov 11, 2024 | 34.7M | – | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits. Stock splits since Dec 31, 2022, from 13F share counts: 1-for-20 in Q1 2026.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.